// App-Quantinova.ai

1501 : Ixekizumab: 52-Week Efficacy and Safety in Radiographic Axial Spondyloarthritis Patients with Prior Inadequate Response/Intolerance to Tumor Necrosis Factor Inhibitors

Researchers

Presenter

  • Joachim Sieper

Principal Investigators

  • Xenofon Baraliakos

  • Filip Van den Bosch

  • Walter P. Maksymowych

  • Joerg Ermann

  • Xiaoqi Li

  • Gaia Gallo

  • Hilde Carlier

  • Lianne Gensler

Medical Centers

  • Hopital Cochin, Paris, France

  • Charite Universitaetsmedizin Berlin, Medical Oncology, Berlin, Germany

  • Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany

  • Ghent University Hospital, Ghent, Belgium

  • University of Alberta, Edmonton, AB, Canada

  • Brigham & Women's Hospital, Boston, MA

  • Eli Lilly and Company, Indianapolis, IN

  • Eli Lilly and Company, Indianapolis, IN

  • University of California, San Francisco, CA

Locations

  • France

  • Germany

  • Belgium

  • Canada

  • United States

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • LY2439821

Outcome

  • N/A

Study Design

  • Randomized

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved